

# Grazia Pennisi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2163951/publications.pdf>

Version: 2024-02-01

16  
papers

566  
citations

1039406

9  
h-index

996533

15  
g-index

16  
all docs

16  
docs citations

16  
times ranked

1027  
citing authors

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 1  | A Genetic and Metabolic Staging System for Predicting the Outcome of Nonalcoholic Fatty Liver Disease. <i>Hepatology Communications</i> , 2022, 6, 1032-1044.  | 2.0 | 6         |
| 2  | A cholestatic pattern predicts major liver-related outcomes in patients with non-alcoholic fatty liver disease. <i>Liver International</i> , 2022, 42, 1037-1048.  | 1.9 | 4         |
| 3  | Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 806-815.e5. | 2.4 | 90        |
| 4  | <i>PCSK9</i> rs11591147 R46L loss-of-function variant protects against liver damage in individuals with NAFLD. <i>Liver International</i> , 2021, 41, 321-332.   | 1.9 | 26        |
| 5  | Exome-Wide Association Study on Alanine Aminotransferase Identifies Sequence Variants in the GPAM and APOE Associated With Fatty Liver Disease. <i>Gastroenterology</i> , 2021, 160, 1634-1646.e7.   | 0.6 | 82        |
| 6  | Impact of direct-acting antivirals (DAAs) on cardiovascular diseases in patients with chronic hepatitis C. <i>Minerva Gastroenterology</i> , 2021, 67, 254-263.  | 0.3 | 2         |
| 7  | Interplay between non-alcoholic fatty liver disease and cardiovascular risk in an asymptomatic general population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2389-2396.  | 1.4 | 6         |
| 8  | <i>NR1H4</i> rs35724 G>C variant modulates liver damage in nonalcoholic fatty liver disease. <i>Liver International</i> , 2021, 41, 2712-2719.   | 1.9 | 6         |
| 9  | PNPLA3 rs738409 C>G Variant Predicts Fibrosis Progression by Noninvasive Tools in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1979-1981.   | 2.4 | 10        |
| 10 | Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , 2021, 75, 786-794.  | 1.8 | 100       |
| 11 | Association Between PNPLA3 rs738409 C>G Variant and Liver-Related Outcomes in Patients With Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 935-944.e3.  | 2.4 | 102       |
| 12 | The Relevance of Noninvasive Tools To Assess Fibrosis in Non-Alcoholic Fatty Liver Disease. <i>Current Pharmaceutical Design</i> , 2020, 26, 3928-3938.  | 0.9 | 3         |
| 13 | Biochemical Biomarkers of NAFLD/NASH. , 2020, , 89-114.  |     | 1         |
| 14 | Pharmacological Therapy of Non-Alcoholic Fatty Liver Disease: What Drugs Are Available Now and Future Perspectives. <i>International Journal of Environmental Research and Public Health</i> , 2019, 16, 4334.   | 1.2 | 21        |
| 15 | Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2310-2319.e6.   | 2.4 | 66        |
| 16 | Antidiabetic Drugs in NAFLD: The Accomplishment of Two Goals at Once?. <i>Pharmaceuticals</i> , 2018, 11, 121.   | 1.7 | 41        |